Assessment of the clinical utility of four NGS panels in myeloid malignancies. Suggestions for NGS panel choice or design.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2020
Historique:
received: 19 07 2019
accepted: 04 01 2020
entrez: 25 1 2020
pubmed: 25 1 2020
medline: 15 4 2020
Statut: epublish

Résumé

The diagnosis of myeloid neoplasms (MN) has significantly evolved through the last few decades. Next Generation Sequencing (NGS) is gradually becoming an essential tool to help clinicians with disease management. To this end, most specialized genetic laboratories have implemented NGS panels targeting a number of different genes relevant to MN. The aim of the present study is to evaluate the performance of four different targeted NGS gene panels based on their technical features and clinical utility. A total of 32 patient bone marrow samples were accrued and sequenced with 3 commercially available panels and 1 custom panel. Variants were classified by two geneticists based on their clinical relevance in MN. There was a difference in panel's depth of coverage. We found 11 discordant clinically relevant variants between panels, with a trend to miss long insertions. Our data show that there is a high risk of finding different mutations depending on the panel of choice, due both to the panel design and the data analysis method. Of note, CEBPA, CALR and FLT3 genes, remains challenging the use of NGS for diagnosis of MN in compliance with current guidelines. Therefore, conventional molecular testing might need to be kept in place for the correct diagnosis of MN for now.

Identifiants

pubmed: 31978184
doi: 10.1371/journal.pone.0227986
pii: PONE-D-19-20399
pmc: PMC6980571
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0227986

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Oncotarget. 2014 Aug 15;5(15):6404-13
pubmed: 25115387
Am J Hematol. 2017 Dec;92(12):1311-1317
pubmed: 28875545
Eur J Haematol. 2015 Jul;95(1):3-15
pubmed: 25645650
Int J Mol Sci. 2016 Mar 24;17(4):440
pubmed: 27023522
J Mol Diagn. 2019 Mar;21(2):228-240
pubmed: 30576870
Br J Haematol. 2015 Oct;171(2):210-214
pubmed: 26085061
J Hematol Oncol. 2017 Jan 18;10(1):18
pubmed: 28100250
Int J Mol Sci. 2016 May 30;17(6):
pubmed: 27248996
Leuk Lymphoma. 2018 Oct;59(10):2273-2286
pubmed: 29164965
Blood Cancer J. 2018 Feb 12;8(2):18
pubmed: 29434284
Leukemia. 2017 Aug;31(8):1661-1670
pubmed: 28484264
Blood Cancer J. 2017 Dec 15;7(12):651
pubmed: 29242635
Arch Pathol Lab Med. 2017 Jun;141(6):759-775
pubmed: 28557600
Am J Hematol. 2015 Aug;90(8):737-8
pubmed: 26017030
Sci Rep. 2017 May 11;7(1):1785
pubmed: 28496180
Leukemia. 2012 May;26(5):1106-7
pubmed: 22124213
Nat Commun. 2016 Aug 22;7:12484
pubmed: 27546487
Blood. 2014 Oct 23;124(17):2705-12
pubmed: 25224413
Clin Cancer Res. 2005 Feb 15;11(4):1372-9
pubmed: 15746035
J Clin Oncol. 2014 Sep 1;32(25):2691-8
pubmed: 25092778
Nat Genet. 2017 Feb;49(2):204-212
pubmed: 27992414
Onco Targets Ther. 2016 Dec 02;9:7355-7365
pubmed: 27980425
J Mol Diagn. 2015 Nov;17(6):635-43
pubmed: 26319364
Nat Commun. 2018 Jan 31;9(1):455
pubmed: 29386642
J Mol Diagn. 2011 Nov;13(6):678-86
pubmed: 21889610
Br J Haematol. 2019 Oct 16;:null
pubmed: 31621063
Cancer Sci. 2018 Jan;109(1):225-230
pubmed: 29151258
Blood. 2001 Apr 15;97(8):2434-9
pubmed: 11290608
J Clin Oncol. 2017 Mar 20;35(9):947-954
pubmed: 28297629
Leukemia. 1996 Dec;10(12):1911-8
pubmed: 8946930
Int J Hematol. 2017 Aug;106(2):175-182
pubmed: 28643018
J Clin Oncol. 2013 Jul 1;31(19):2428-36
pubmed: 23690417
J Clin Oncol. 2017 Mar 20;35(9):934-946
pubmed: 28297624
Leukemia. 2019 Aug;33(8):1851-1867
pubmed: 30696948
Leukemia. 2013 Sep;27(9):1870-3
pubmed: 23604229
Haematologica. 2015 Sep;100(9):1117-30
pubmed: 26341525
Blood. 2017 Jul 27;130(4):410-423
pubmed: 28600336
J Mol Diagn. 2018 Mar;20(2):203-214
pubmed: 29429887
Am J Clin Pathol. 2017 May 1;147(5):444-452
pubmed: 28419183
Leukemia. 2010 Jul;24(7):1290-8
pubmed: 20508609
Leukemia. 2013 Sep;27(9):1852-60
pubmed: 23628959
Blood. 2002 Feb 15;99(4):1332-40
pubmed: 11830484
Leukemia. 2018 Jan;32(1):227-229
pubmed: 28832022
Leukemia. 2011 Jun;25(6):1056-8
pubmed: 21415853
Am J Hematol. 2013 Apr;88(4):306-11
pubmed: 23460398
Blood Cancer J. 2016 Feb 05;6:e393
pubmed: 26849014
Blood. 2016 Aug 4;128(5):686-98
pubmed: 27288520
Br J Cancer. 2009 Apr 21;100(8):1343-6
pubmed: 19277035
Am J Hematol. 2011 Oct;86(10):866-8
pubmed: 21922527
Nat Genet. 2013 Oct;45(10):1232-7
pubmed: 23955599
Leuk Lymphoma. 2016;57(3):520-36
pubmed: 26693794
N Engl J Med. 2013 Dec 19;369(25):2391-2405
pubmed: 24325359
Blood. 2016 May 19;127(20):2391-405
pubmed: 27069254
Blood. 2013 Mar 28;121(13):2522-8
pubmed: 23355535
Clin Biochem. 2018 Nov;61:34-39
pubmed: 30176240
Blood. 2018 Sep 20;132(12):1225-1240
pubmed: 29930011
Blood Cancer J. 2018 Nov 12;8(11):113
pubmed: 30420667
Leukemia. 2012 May;26(5):1135-7
pubmed: 22064353
Nat Genet. 2014 Jan;46(1):33-8
pubmed: 24316979
Blood. 2014 Feb 6;123(6):914-20
pubmed: 24335498
Oncogene. 2017 Feb 23;36(8):1038-1047
pubmed: 27593934
Nat Biotechnol. 2011 Jan;29(1):24-6
pubmed: 21221095
Blood. 2017 Jan 26;129(4):424-447
pubmed: 27895058
Leukemia. 2016 Nov;30(11):2270-2273
pubmed: 27479181
Genes Chromosomes Cancer. 2012 Oct;51(10):910-24
pubmed: 22674490
Semin Hematol. 2014 Oct;51(4):282-97
pubmed: 25311741
Leukemia. 2014 Feb;28(2):241-7
pubmed: 24220272
Blood. 2016 Mar 24;127(12):1551-8
pubmed: 26755712
Am J Hum Genet. 2011 Jan 7;88(1):115-20
pubmed: 21211618
Blood. 2013 Nov 21;122(22):3616-27; quiz 3699
pubmed: 24030381
Blood. 2016 Jan 21;127(3):325-32
pubmed: 26423830
Nat Med. 2016 Feb;22(2):128-34
pubmed: 26845405
Oncotarget. 2018 Jul 10;9(53):30128-30145
pubmed: 30046393
Blood. 2016 Jan 21;127(3):333-42
pubmed: 26450985
Leuk Res. 2011 Nov;35(11):1537-9
pubmed: 21794913
Cancer. 2018 Nov 15;124(22):4301-4313
pubmed: 30291792
Best Pract Res Clin Haematol. 2017 Dec;30(4):312-316
pubmed: 29156201
Int J Hematol. 2017 Jun;105(6):732-742
pubmed: 28447248
Blood. 2017 Apr 13;129(15):2103-2110
pubmed: 28179280
Diagn Pathol. 2016 Jan 22;11:11
pubmed: 26796102
BMC Cancer. 2012 Jul 23;12:304
pubmed: 22823977
Blood. 2017 Feb 16;129(7):811-822
pubmed: 28064238
Genes Chromosomes Cancer. 2018 Aug;57(8):401-408
pubmed: 29663558

Auteurs

Almudena Aguilera-Diaz (A)

Advanced Genomics Laboratory, Hemato-Oncology, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain.
Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.

Iria Vazquez (I)

Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.
Hematological Diseases Laboratory, CIMA LAB Diagnostics, University of Navarra, Pamplona, Spain.

Beñat Ariceta (B)

Hematological Diseases Laboratory, CIMA LAB Diagnostics, University of Navarra, Pamplona, Spain.

Amagoia Mañú (A)

Hematological Diseases Laboratory, CIMA LAB Diagnostics, University of Navarra, Pamplona, Spain.

Zuriñe Blasco-Iturri (Z)

Hematological Diseases Laboratory, CIMA LAB Diagnostics, University of Navarra, Pamplona, Spain.

Sara Palomino-Echeverría (S)

Hematological Diseases Laboratory, CIMA LAB Diagnostics, University of Navarra, Pamplona, Spain.

María José Larrayoz (MJ)

Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.
Hematological Diseases Laboratory, CIMA LAB Diagnostics, University of Navarra, Pamplona, Spain.

Ramón García-Sanz (R)

Hematology Department, University Hospital of Salamanca, IBSAL and CIBERONC, Salamanca, Spain.

María Isabel Prieto-Conde (MI)

Hematology Department, University Hospital of Salamanca, IBSAL and CIBERONC, Salamanca, Spain.

María Del Carmen Chillón (M)

Hematology Department, University Hospital of Salamanca, IBSAL and CIBERONC, Salamanca, Spain.

Ana Alfonso-Pierola (A)

Hematology Department, Clinica Universidad de Navarra (CUN), Pamplona, Spain.

Felipe Prosper (F)

Advanced Genomics Laboratory, Hemato-Oncology, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain.
Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.
Hematology Department, Clinica Universidad de Navarra (CUN), Pamplona, Spain.

Marta Fernandez-Mercado (M)

Advanced Genomics Laboratory, Hemato-Oncology, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain.
Hematological Diseases Laboratory, CIMA LAB Diagnostics, University of Navarra, Pamplona, Spain.
Biomedical Engineering Department, School of Engineering, University of Navarra, San Sebastian, Spain.

María José Calasanz (MJ)

Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.
Hematological Diseases Laboratory, CIMA LAB Diagnostics, University of Navarra, Pamplona, Spain.
Scientific Co-Director of CIMA LAB Diagnostics, CIMA LAB Diagnostics, University of Navarra, Pamplona, Spain.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH